Trial Profile

A Phase 2, Single-Arm, Open-Lable, Multicenter Study of Duvelisib, a Dual Inhibitor of Phosphoinositide-3-kinase-d (PI3K-d) and PI3K-y, in Subjects With Relapsed and Refractory Follicular Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Apr 2022 According to a CSPC ZhongQi Pharmaceutical Technology media release, Duvelisib Capsules for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/rFL) who have already received at least two systematic treatments has received registration approval by the National Medical Products Administration of the People's Republic of China.
08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
26 Aug 2020 Status changed from recruiting to active, no longer recruiting, according to a CSPC Pharmaceutical Group media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com